ERBB2 and breast carcinoma: Over 20% of breast cancers exhibit overexpression of HER-2 human epidermal growth factor receptor-2 (HER-2) (10); therefore, targeting this receptor may represent an attractive target for nanoparticles loaded with anticancer drugs.